Learning Objectives: -Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) FL. -Develop an understanding of available clinical trial findings supporting the use of bispecific antibodies targeting CD20 and CD3 for the management of R/R FL. -Identify patients with R/R FL who may be candidates for chimeric antigen receptor T-cell therapy directed at CD19. -Assess recently presented clinical research findings with the use of CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in the care of patients with R/R FL. -Evaluate published clinical research findings establishing the efficacy and safety of combined Bruton tyrosine kinase inhibitor/anti-CD20 antibody therapy for patients with R/R FL. -Consider recommended approaches to prevent, ameliorate and manage toxicities associated with various therapies commonly used in the care of patients with R/R FL. -Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 40946 US Highway 19 N
Pricing
CME included with membership · $19.99/mo
| Regular Membership | Free |
| Affiliated Health Professional Membership | Free |
| MENASA Group Explorer | Free |
| MENASA Group Elite Member | $19.99/mo |
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Oncology
- Metabolic & Bariatric Surgery
- Nephrology
- Neurology
- Neuroradiology
- Ophthalmology
- Patient Education & Health Literacy
- Pediatric Gastroenterology
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Thoracic Surgery
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1.25 credits
- MOC · Up to 1.25 points
- Commercial Support
-
ReleasedOct 10, 2025
-
Last day to claim creditOct 11, 2026 1 day left
-
Physicians’ Education Resource (CME Track) Community Practice Connections(TM): Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
-
Efficient CME, CME Outfitters, LLC The Shifting Landscape of Follicular Lymphoma (FL): A Community and Academic Dialogue Addressing the Growing Role of T-Cell Therapies
-
Medscape, LLC Tailoring Bispecific Antibodies to Individualize R/R Follicular Lymphoma: A Case Based Discussion
-
Society of Hematologic Oncology +1 Relapsed/Refractory CLL/SLL Clinical Insights: Navigating Novel Therapy Integration and Sequencing Considerations – Mobile Microlearning
-
Society of Hematologic Oncology +1 Optimizing Treatment Approaches and Clinical Practice for Relapsed/Refractory Multiple Myeloma
-
The Society of Hematologic Oncology +1 Optimizing Treatment Approaches and Clinical Practice for Relapsed/Refractory Multiple Myeloma | Evolving Role of Bispecific Antibody Therapy in the Treatment Landscape for RRMM
